{"id":25031,"date":"2012-02-18T05:31:11","date_gmt":"2012-02-18T10:31:11","guid":{"rendered":"http:\/\/asweetlife.org\/?p=25031"},"modified":"2015-12-28T07:36:24","modified_gmt":"2015-12-28T12:36:24","slug":"type-2-diabetes-drug-byetta-recommended-as-add-on-therapy-to-insulin-by-chmo","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=25031","title":{"rendered":"Type 2 Diabetes Drug Byetta Recommended as Add-on Therapy to Insulin"},"content":{"rendered":"<div style=\"text-align: justify;\"><a href=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/02\/Amylin-Lilly-Logo-1.png\" rel=\"mfp\"><img decoding=\"async\" class=\"alignleft size-full wp-image-25035 lazyload\" title=\"Amylin Lilly Logo\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" data-src=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/02\/Amylin-Lilly-Logo-1.png\" alt=\"\" width=\"150\" height=\"44\" \/><\/a>The\u00a0European Medicines Agency&#8217;s (EMA)\u00a0Committee for Medicinal Products for Human Use (CHMP)\u00a0has issued a positive opinion in the European Union (EU) for the expanded use of Byetta (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and\/or Actos\u00ae (pioglitazone), for the treatment of type 2 diabetes in adults.\u00a0The CHMP&#8217;s decision is now referred for final action to the European Commission, which has the authority to approve medicines for the EU. The Commission usually decides on CHMP recommendations within two to three months.\u00a0<\/div>\n<div style=\"text-align: justify;\">\n<div>\u00a0<\/div>\n<\/div>\n<div style=\"text-align: justify;\">The double-blind clinical trial evaluating\u00a0 Byetta\u00a0\u00a0as an add-on therapy to insulin glargine was published in Annals of Internal Medicine. In the 30-week study,\u00a0 Byetta\u00a010 micrograms or placebo was added to existing insulin glargine therapy (with or without metformin, pioglitazone or both), which was titrated to achieve target fasting glucose levels. At study entry, patients who may have been at increased risk of hypoglycemia (A1c less than or equal to 8 percent) reduced their dose of insulin glargine by 20 percent. Five weeks after randomization, all patients had insulin doses titrated to achieve target fasting glucose levels. The primary endpoint was reduction in A1c, a measure of average blood sugar over three months; secondary endpoints included change in body weight along with other parameters of glucose control, cardiovascular health, hypoglycemia and patient-reported outcomes.\u00a0<\/div>\n<div style=\"text-align: justify;\">\u00a0<\/div>\n<div style=\"text-align: justify;\">After 30 weeks of treatment,\u00a0 Byetta\u00a0\u00a0demonstrated a statistically significant reduction in A1c compared to placebo, lowering A1c by 1.7 percentage points from a baseline of 8.3 percent. Patients treated with optimized insulin glargine plus placebo experienced a 1.0 percentage point decrease in A1c from a baseline of 8.5 percent. Patients who added\u00a0 Byetta\u00a0\u00a0to their insulin glargine regimen saw their weight decrease by an average of 4 pounds, compared with an increase of 2 pounds in patients who were treated with optimized insulin glargine plus placebo.\u00a0 Byetta\u00a0\u00a0is not indicated for the management of obesity and weight loss was a secondary endpoint in the trial. Fasting glucose change and hypoglycemia incidence were similar between treatment groups.\u00a0<\/div>\n<div style=\"text-align: justify;\">\u00a0<\/div>\n<div style=\"text-align: justify;\">Thirteen\u00a0 Byetta\u00a0\u00a0recipients and one placebo recipient (9 percent vs. 1 percent) discontinued the study because of adverse events (p less than 0.010); rates of nausea (41 percent vs. 8 percent), diarrhea (18 percent vs. 8 percent), vomiting (18 percent vs. 4 percent), headache (14 percent vs. 4 percent) and constipation (10 percent vs. 2 percent) were higher with Byetta than with placebo. Hypoglycemia was similar for both groups; major hypoglycemia occurred twice in one patient receiving insulin glargine without\u00a0 Byetta.\u00a0<\/div>\n<div style=\"text-align: justify;\">\u00a0<\/div>\n<div style=\"text-align: justify;\">In November 2011, Lilly and Amylin announced that they amicably terminated their decade-long collaboration. As part of the transition plan outside the U.S., Amylin will assume responsibility for exenatide product commercialization efforts on a market-by-market basis by the end of 2013. Amylin will work with Lilly on plans for markets outside the U.S. during the transition period. Amylin intends to provide uninterrupted patient supply in all markets where exenatide products are launched, as well as additional markets in the future. Both companies are committed to ensuring a seamless transition of global product responsibility to Amylin while maintaining continuity of patient care. Amylin anticipates working with one or more partners outside the U.S. in order to maximize the global potential of this innovative molecule and achieve greater operational flexibility and efficiency.<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The European Medicines Agency&#8217;s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion in the European Union (EU) for the expanded use of Byetta (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and\/or Actos\u00ae (pioglitazone)&#8230;<\/p>\n","protected":false},"author":131,"featured_media":29356,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1443],"tags":[277],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Type 2 Diabetes Drug, Byetta, Recommended as Add-on Therapy to Insulin by CHMO<\/title>\n<meta name=\"description\" content=\"The CHMP issued a positive opinion in the EU for the expanded use of Byetta as an add-on therapy to basal insulin, with or without metformin and\/or Actos\u00ae (pioglitazone), for the treatment of type 2 diabetes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=25031\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ASweetLife Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=25031\",\"url\":\"https:\/\/asweetlife.org\/?p=25031\",\"name\":\"Type 2 Diabetes Drug, Byetta, Recommended as Add-on Therapy to Insulin by CHMO\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=25031#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=25031#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/02\/Amylin-Lilly-Logo.jpg\",\"datePublished\":\"2012-02-18T10:31:11+00:00\",\"dateModified\":\"2015-12-28T12:36:24+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\"},\"description\":\"The CHMP issued a positive opinion in the EU for the expanded use of Byetta as an add-on therapy to basal insulin, with or without metformin and\/or Actos\u00ae (pioglitazone), for the treatment of type 2 diabetes.\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=25031#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=25031\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=25031#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/02\/Amylin-Lilly-Logo.jpg\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/02\/Amylin-Lilly-Logo.jpg\",\"width\":185,\"height\":139,\"caption\":\"Amylin Lilly Logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=25031#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Type 2 Diabetes Drug Byetta Recommended as Add-on Therapy to Insulin\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\",\"name\":\"ASweetLife Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"caption\":\"ASweetLife Team\"},\"url\":\"https:\/\/asweetlife.org\/?author=131\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Type 2 Diabetes Drug, Byetta, Recommended as Add-on Therapy to Insulin by CHMO","description":"The CHMP issued a positive opinion in the EU for the expanded use of Byetta as an add-on therapy to basal insulin, with or without metformin and\/or Actos\u00ae (pioglitazone), for the treatment of type 2 diabetes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=25031","twitter_misc":{"Written by":"ASweetLife Team","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=25031","url":"https:\/\/asweetlife.org\/?p=25031","name":"Type 2 Diabetes Drug, Byetta, Recommended as Add-on Therapy to Insulin by CHMO","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=25031#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=25031#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/02\/Amylin-Lilly-Logo.jpg","datePublished":"2012-02-18T10:31:11+00:00","dateModified":"2015-12-28T12:36:24+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585"},"description":"The CHMP issued a positive opinion in the EU for the expanded use of Byetta as an add-on therapy to basal insulin, with or without metformin and\/or Actos\u00ae (pioglitazone), for the treatment of type 2 diabetes.","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=25031#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=25031"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=25031#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/02\/Amylin-Lilly-Logo.jpg","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2012\/02\/Amylin-Lilly-Logo.jpg","width":185,"height":139,"caption":"Amylin Lilly Logo"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=25031#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"Type 2 Diabetes Drug Byetta Recommended as Add-on Therapy to Insulin"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585","name":"ASweetLife Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","caption":"ASweetLife Team"},"url":"https:\/\/asweetlife.org\/?author=131"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/25031"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25031"}],"version-history":[{"count":0,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/25031\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/29356"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25031"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25031"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25031"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}